Therapy of Primary Liver Cancer

• Published in: Innovation (New York, NY) NY), 2020-08, Vol.1 (2), p.100032-100032, Article 100032
• Main Authors: Feng, Mei, Pan, Yisheng, Kong, Ruirui, Shu, Shaokun
• Format: Article
• Language: English
• Subjects: combined HCC-ICC; hepatocellular carcinoma; intrahepatic cholangiocarcinoma; PLC therapy; primary liver cancer; Review
• ISSN: 2666-6758; 2666-6758
• DOI: 10.1016/j.xinn.2020.100032

Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is the leading cause of cancer-related deaths and the incidence rate is predicted to rise in the coming decades. PLC can be categorized into three major histological subtypes: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC. These subtypes are distinct with respect to epidemiology, clinicopathological features, genetic alterations, and clinical managements, which are thoroughly summarized in this review. The state of treatment strategies for each subtype, including the currently approved drugs and the potential novel therapies, are also discussed. [Display omitted] •Primary liver cancer comprises HCC, ICC, cHCC-ICC, which are markedly distinct in their epidemiology, clinical features and response to therapy•HCC is viral infection-related malignancy with specific histological features, whereas ICC is associated with chronic liver inflammation•HCC is prone to respond to targeted therapy, immunotherapy, and antiviral agents, whereas ICCs are benefit from chemotherapy, targeted therapy, and immunotherapy•Combined cHCC-ICC subclass shows strong ICC-like features and is considered to be treated like ICC, whereas mixed cHCC-ICC subclass resembles HCC and is treated like HCC